Investors considering a purchase of Harrow Inc (Symbol: HROW) stock, but tentative about paying the going market price of $35.48/share, might benefit from considering selling puts among the ...

Harrow's focused acquisition model in ophthalmic drugs enables high growth, with a diversified portfolio and limited R&D expenses. My DCF analysis suggests a fair value of $72.75 per share—nearly 100% ...

Investors considering a purchase of Harrow Inc (Symbol: HROW) shares, but tentative about paying the going market price of $32.54/share, might benefit from considering selling puts among the ...

Harrow is a company focused on eye health with a strong distribution platform and CEO ownership. Q3 earnings were below expectations, and guidance was lowered, raising concerns about operational ...

Daniel is a Writer here at Game Rant and has been a content writer for several years. He loves playing any game he can get his hands on, whether on his Playstation or phone. His favorite game genres ...